Evidence Needed to Support Genomic Population Screening - Session 5

Explore the current state and future prospects of population genomic screening in this comprehensive conference session from the National Human Genome Research Institute's Genomic Medicine XV meeting. Delve into the value proposition, cost-effectiveness, and real-world experiences of genomic screening initiatives. Learn about uptake and follow-up challenges, focusing on the Alabama Genomic Health Initiative. Examine the opportunities and lessons learned from APOL1 screening, and engage in a discussion on the evidence needed to support widespread genomic screening programs. Gain insights from leading experts in the field as they address barriers, opportunities, and potential impacts on clinical practice and outcomes.

- Introductions Rex Chilshom
- Day 1 Recap Teri Manolio
- The Value Proposition for Population Genomic Screening Marc Williams
- Cost-effectiveness of population genomic screening David Veenstra
- Uptake and Follow-up on Population Genomic Screening: Experience in the Alabama Genomic Health Initiative Bruce Korf
- APOL1 Screening: Opportunities, Lessons Learned and Evidence to Support Screening Carol Horowitz
- Discussion